Chronic inflammatory demyelinating polyradiculoneuropathy
Conditions
Interventions
Cyclosporin A is given orally at an initial dose of 3 mg/kg/day. The dosage of cyclosporine A is adjusted to keep a serum trough concentration between 100 and 150 ng/ml. Adiministration of high-dose i
Sponsors
CIDP Study Group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Definite or probable CIDP according to classification criteria of the EFNS/PNS CIDP guideline. 2. Exacerbations more than 4 times per year. 3. INCAT disability scale higher than grade 2 in upper limbs or grade 1 in lower limbs. 4. Written informed consent
Exclusion criteria
Exclusion criteria: 1. polyneuropathy of other causes 2. multifocal motor neuropathy 3. positive for anti-MAG antibody 4. treated with prednisolone at a dose higher than 30 mg/day 5. previous history of cyclosporin A 6. neuron-Behcet 7. malignancy 8. chronic active inflammatory diseases 9. poor-controlled hypertension 10. congestive heart failure 11. liver cirrhosis 12. nephritic syndrome 13. hyperkalemia 14. gout 15. diabetes mellitus 16. pancreatitis 17. severe central nervous disorders 18. pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| neurological symptom, frequency of high-dose intravenous immunoglobulin, toxicity | — |
Countries
Japan
Contacts
Public ContactShu-ichi Ikeda
Shinshu University School of Medicine Asahi 3-1-1, Matsumoto, Nagano, 390-8621, Japan
Outcome results
None listed